Brean Capital Maintains Buy On Chimerix Following Preliminary Data Release At IDWeek 2014 Meeting
In a research report released today, Brean Capital analyst Jonathan Aschoff maintained a Buy rating on Chimerix (NASDAQ:CMRX) with a $33 price target, as preliminary data from the pilot portion of the company’s Phase 3 AdVise trial were presented at the IDWeek 2014 meeting, showing improved survival with brincidofovir (BCV) in patients with adenovirus.
Aschoff wrote, “The AdVise trial continues to enroll pediatric and adult patients with adenovirus infection to receive brincidofovir BIW for 12 weeks. The safety and tolerability profile of brincidofovir in these initial 26 patients was consistent with expectations, with only 3 patients (two pediatric and one adult) discontinuing due to adverse events. Six of the 20 pediatric patients and one of the 6 adults had at least one fatal adverse event. Of the 6 patients with adenovirus-related diarrhea at entry, 3 experienced improvement of symptoms and 3 remained stable.”
According to TipRanks.com, which measures analysts’ and bloggers’ success rate based on how their calls perform, analyst Jonathan Aschoff has a total average return of 11.7% and a 49.4% success rate. Aschoff has an 8.8% average return when recommending CMRX, and is ranked #221 out of 3340 analysts.